Recombinant Human KIR2DL2/CD158b1 Fc Chimera Protein, CF

• Reactivity: Hu
• Applications: Bioactivity
• Format: Carrier-Free

Recombinant Human KIR2DL2/CD158b1 Fc Chimera Protein, CF Summary

• Details of Functionality: Measured by its ability to bind HEK293T human embryonic kidney cells in a flow cytometry assay. When 1 μg of Recombinant Human KIR2DL2/CD158b1 Fc Chimera is added to 5 x 10⁵ HEK293T cells, >20% of the cells will bind to the protein.
• Source: Mouse myeloma cell line, NS0-derived human KIR2DL2/CD158b1 protein
  

  Human KIR2DL2 (His22 - His245) Accession # P43627	IEGRMD	Human IgG1 (Pro100 - Lys330)
  N-terminus		C-terminus

• Accession #: P43627
• N-terminal Sequence: His22
• Structure / Form: Disulfide-linked homodimer
• Protein/Peptide Type: Recombinant Proteins
• Gene: KIR2DL2
• Purity: >90%, by SDS-PAGE under reducing conditions and visualized by silver stain
• Endotoxin Note: <1.0 EU per 1 μg of the protein by the LAL method.

Applications/Dilutions

• Dilutions:
  • Bioactivity
• Theoretical MW: 51.2 kDa (monomer).
  Disclaimer note: The observed molecular weight of the protein may vary from the listed predicted molecular weight due to post translational modifications, post translation cleavages, relative charges, and other experimental factors.
• SDS-PAGE: 65-75 kDa, reducing conditions

Packaging, Storage & Formulations

• Storage: Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
  • 12 months from date of receipt, -20 to -70 °C as supplied.
  • 1 month, 2 to 8 °C under sterile conditions after reconstitution.
  • 3 months, -20 to -70 °C under sterile conditions after reconstitution.
• Buffer: Lyophilized from a 0.2 μm filtered solution in PBS.
• Purity: >90%, by SDS-PAGE under reducing conditions and visualized by silver stain
• Reconstitution Instructions: Reconstitute at 100 μg/mL in PBS.

Notes

This product is produced by and ships from R&D Systems, Inc., a Bio-Techne brand.

Alternate Names for Recombinant Human KIR2DL2/CD158b1 Fc Chimera Protein, CF

• CD158b1
• CL-43
• KIR2DL2
• NKAT6

Background

KIR2DL2 (2DL2, formerly NKAT6, designated CD158b) is a 348 amino acid (aa) type I transmembrane glycoprotein that belongs to the human killer cell Ig‑like receptor (KIR) family (1, 2). KIRs are expressed on human CD56^dim NK cells and T cell subsets, and regulate effector functions in the innate immune system (1 ‑ 3). KIRs are named for the number of Ig‑like domains (2D or 3D) in the extracellular domain (ECD), and whether they have long or short (L, S) cytoplasmic tails (1 ‑ 3). Individuals will express varying subsets of inhibiting and activating KIRs with varying polymorphisms (1, 4). Like other inhibiting KIRs, KIR2DL2 has two ITIM domains within its long tail that block activating receptor clustering (2, 5). Within the ECD, KIR2DL2 shares very high aa sequence identity (98%) with KIR2DL3. The two segregate as alleles of the same gene, although KIR2DL2 shows higher avidity for HLA‑C1 ligands (1, 6). Extracellular aa identity is also high for KIR2DL1 (92%). The three together recognize and inhibit NK cytotoxicity against cells expressing any HLA‑C allotype, allowing self‑recognition, but also conferring susceptibility to leukemia (1 ‑ 3). KIR2DL2 recognizes Asn80‑containing HLA‑C1 and, more weakly, Lys80‑containing C2 allotypes (1, 6 ‑ 8). KIR2DL2 can impact both innate and adaptive immunity, contributing to either viral persistence or antiviral immunity, depending on the HLA class I molecules expressed by the individual (9).

1. Purdy, A.K. and Campbell, K.S. (2009) Cancer Biol. Ther. 8:13.
2. Lanier, L. L. (2005) Annu. Rev. Immunol. 23:225.
3. Kulkarni, S. et al. (2008) Sem. Immunol. 20:343.
4. Middleton, D. and F. Gonzelez (2009) Immunology 129:8.
5. Abeyweera, T.P. et al. (2011) J. Cell Biol. 192:675.
6. Moesta, A.K. et al. (2008) J. Immunol. 180:3969.
7. Boyington, J.C. et al. (2000) Nature 405:537.
8. Snyder, G.A. et al. (1999) Proc. Natl. Acad. Sci. USA 96:3864.
9. Seich al Basatena, N-K. et al. (2011) PLoS Pathog. 7:e1002270.

Publications for KIR2DL2/CD158b1 (3015-KR)(3)

Publications using 3015-KR

• N Wauquier, C Petitdeman, N Tarantino, C Maucourant, M Coomber, V Lungay, J Bangura, P Debré, V Vieillard HLA-C-restricted viral epitopes are associated with an escape mechanism from KIR2DL2+ NK cells in Lassa virus infection EBioMedicine, 2019;0(0):. 2019 [PMID: 30711514] (Flow Cytometry, Human)
• Cassidy S, Mukherjee S, Myint T, Mbiribindi B, North H, Traherne J, Mulder A, Claas F, Purbhoo M, Das J, Khakoo S Peptide selectivity discriminates NK cells from KIR2DL2- and KIR2DL3-positive individuals. Eur J Immunol, 2015;45(2):492-500. 2015 [PMID: 25359276] (Bioassay, N/A)
• Fadda L, Korner C, Kumar S, van Teijlingen NH, Piechocka-Trocha A, Carrington M, Altfeld M HLA-Cw*0102-Restricted HIV-1 p24 Epitope Variants Can Modulate the Binding of the Inhibitory KIR2DL2 Receptor and Primary NK Cell Function. PLoS Pathog., 2012;8(7):e1002805. 2012 [PMID: 22807681] (Flow Cytometry, Human)

Bioinformatics

• Gene Symbol: KIR2DL2
• Uniprot:
  • P43627()